Open Nav

American Gene Technologies

  • Jeff Galvin, American Gene Technologies

Fund Functional HIV Cure to First Human Efficacy

  • Date:Wednesday, October 17
  • Time:2:15 PM - 2:30 PM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: immune-oncology, infectious disease, and monogenic disorders. AGT expects to take its patented lead candidate for an HIV Cure into the clinic in 2019, and has a novel immuno-oncology(I/O) approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel I/O approach have already been granted, and AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine. AGT has developed a (patent-pending) modified gene that is able to express therapeutic levels of phenylalanine hydroxylase (PAH) which it is deploying, for development of a cure for Phenylketonuria (PKU). AGT expects to begin clinical activities for PKU in 2019, and liver cancer (AGT’s first I/O therapy) in 2020.
  • Company Website:
  • Company HQ City:Rockville
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • CEO/Top Company Official:Jeff Galvin
  • Year Founded:2008
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :Immunotherapy for a Functional Cure of HIV
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners) :3
  • Previous and Current Investors:HNWI
  • Size of Last Investment Round:$15 Million
  • Total Amount Raised to Date, In All Rounds:$24 million
Jeff Galvin
American Gene Technologies